Loading stock data…
$1.26-0.02 (-1.57%)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea.
Nyxoah SA in the Healthcare sector is trading at $1.26 with a market capitalization of $146M. Wall Street consensus targets $4.17 (3 analysts), implying a +230.6% move over the next 12 months. The stock is currently near its 52-week low of $1.25, remaining 54.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.67M↑ | $6.37M↑ | $5.64M↑ | $1.97M↑ | $1.34M |
| Gross Profit | $4.58M↑ | $3.64M↑ | $3.63M↑ | $1.19M↑ | $850,000 |
| Operating Income | -$20.55M↓ | -$20.50M↓ | -$18.26M↑ | -$24.20M↓ | -$19.85M |
| Net Income | -$32.96M↓ | -$15.94M↑ | -$23.51M↑ | -$23.58M↓ | -$20.61M |
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The c...